FibroBiologics, Inc. 8-K

What Happened
FibroBiologics, Inc. announced on April 16, 2026 that its board of directors amended and restated the company’s bylaws to change Section 2.07 (Quorum). The quorum requirement for stockholder meetings was revised from “a majority in voting power” to “the holders of one‑third in voting power” of shares entitled to vote. The amended bylaws text was filed as Exhibit 3.1 to the company’s Form 8‑K (filed April 17, 2026).

Key Details

• Amendment date: April 16, 2026; Form 8‑K filed April 17, 2026.
• Bylaw change: Section 2.07 quorum requirement reduced from a majority of voting power to one‑third of voting power.
• Restated bylaws: The Board amended and restated the Amended and Restated Bylaws; the new Section 2.07 retains provisions on adjournment and quorum continuity.
• Exhibit included: Exhibit 3.1 (Second Amended and Restated Bylaws) was furnished with the filing; the 8‑K was signed by CEO Pete O’Heeron.

Why It Matters
Lowering the quorum threshold makes it easier for the company to constitute a valid shareholder meeting and transact business with lower shareholder turnout. For investors, this is a governance change that can affect how readily proposals or elections proceed at meetings—both routine and potentially contested items—because fewer votes are required to reach quorum. The filing is procedural and does not report financial results or executive changes.